GlassScriptPhysician profile
Fidencio Davalos
NPI 1265872725
$19,545.09
in general payments reported to CMS, 2019-2025
37 companies · $3,777 in 2025
The $3,777 reported for 2025 was more than what 91% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $386 · 2021: $2,258 · 2022: $5,539 · 2023: $4,191 · 2024: $3,215 · 2025: $3,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,767.08 |
| Education | $415.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,265.39 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Intuitive Surgical, INC. | $3,200.31 | 2021-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $2,376.15 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,934.09 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,322.58 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,112.80 | 2020-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $715.29 | 2020-2024 | Yupelri |
| Grifols USA, LLC | $579.72 | 2021-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $472.72 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $447.33 | 2022-2025 | Winrevair, Capvaxive, Keytruda |
| Csl Behring | $427.03 | 2020-2025 | Hizentra |
| Insmed, INC. | $355.71 | 2020-2025 | Arikayce, Brinsupri |
| Amgen INC. | $340.04 | 2021-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $336.54 | 2023-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $299.40 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $273.24 | 2025 | Yupelri |
| Philips North America LLC | $243.20 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $243.01 | 2021-2024 | |
| Verona Pharma, INC. | $223.01 | 2025 | Ohtuvayre |
| Abiomed | $196.19 | 2021-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $177.16 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $154.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.17 | 2021-2023 | |
| Genentech USA, INC. | $127.06 | 2020-2023 | Xolair |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| United Therapeutics Corporation | $96.07 | 2021-2023 | Tyvaso |
| Janssen Pharmaceuticals, INC | $65.97 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $64.41 | 2020 | |
| Pulmonx Corporation | $39.10 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $38.53 | 2025 | Hyqvia |
| Haemonetics Corporation | $34.83 | 2023 | |
| Vifor Pharma, INC. | $25.92 | 2025 | Zemaira |
| Siemens Medical Solutions USA, INC. | $22.61 | 2024 | Cios Spin |
| La Jolla Pharmaceutical Company | $20.89 | 2025 | Giapreza |
| Electromed, INC. | $16.80 | 2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $16.20 | 2022 | |
| Advanced Respiratory, INC | $15.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fidencio Davalos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.